Lupin Limited, a global pharmaceutical company based in Mumbai, India, has received approval from the United States Food and Drug Administration (FDA) for its generic version of Fluconazole Tablets, challenging Pfizer’s popular brand Diflucan. The approval allows Lupin to market and sell Fluconazole Tablets in the US, providing a more affordable alternative to Pfizer’s product.
The generic Fluconazole Tablets, available in strengths of 50 mg, 100 mg, 150 mg, and 200 mg, will be manufactured at Lupin’s facility in Pithampur, India. This approval comes as a significant achievement for Lupin, as it opens up a market with estimated annual sales of USD 43 million in the US.
Lupin is an innovation-led pharmaceutical company with a strong presence in over 100 markets worldwide. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs. Lupin has established itself as a leader in the cardiovascular, anti-diabetic, and respiratory segments, and it also has a significant presence in areas such as anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health.
With 15 manufacturing sites and 7 research centers, Lupin has a global workforce of more than 20,000 professionals. The company prides itself on its commitment to research and development, investing 7.9% of its revenue in these areas in the last financial year. Lupin’s dedication to innovation has earned it the reputation of being the third-largest pharmaceutical company in the US by prescriptions.
For more information about Lupin and its products, please visit their official website. You can also follow Lupin on social media platforms such as Twitter, LinkedIn, and Facebook to stay updated on their latest developments.
In summary, Lupin’s FDA approval for its generic Fluconazole Tablets poses a challenge to Pfizer’s Diflucan. This approval allows Lupin to bring a cost-effective alternative to the US market, benefiting patients and potentially impacting sales of the brand-name product. With its strong presence and commitment to innovation, Lupin continues to make strides in the pharmaceutical industry.
